DiMe Webinar: With tightening digital health funding and escalating expectations, how can innovators efficiently construct evidence for their products?

The digital health sector in Q1 of 2024 is experiencing an interesting shift – despite $2.7B investment, 133 digital health venture deals are showing higher deal volume at lower check sizes. Developers face ongoing demands to demonstrate tangible clinical and economic outcomes, but with tightening budgets and on shorter timelines. With such a dynamic landscape, there is a pivotal debate taking place across the industry focused on the optimal strategy for 1) building the right evidence strategy using effective methodologies with limited timelines, and 2) addressing the needs and expectations of a diverse range of stakeholders and decision-makers — including payers, purchasers, clinicians, and patients — in the development and deployment of DHTs for broad acceptance.